ArticleJCI insight2021
Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection.
Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Innate-like T Cell Biology in the Tumor Microenvironment Implications for Cancer Immunotherapy.Cells · 2026Review
- Dual Roles of MAIT Cells in the Tumor Microenvironment: Implications for Cancer Immunity and Therapy.Immune network · 2026Review
- Redefining cell therapy: CAR-engineered innate immune cells to conquer solid and hematologic malignancies.Molecular biology reports · 2026Review
- Abnormal T-Cell activation and cytotoxic T-Cell frequency discriminate symptom severity in myalgic encephalomyelitis/chronic fatigue syndrome.Journal of translational medicine · 2025Article
- Breakthrough for Anticancer Immunotherapy: Current Advances in Manufacturing Protocols of Chimeric Antigen Receptor-Based Therapies.Antibodies (Basel, Switzerland) · 2025Review
- Mucosal-Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2025Review
- Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18.Nature communications · 2025Article
- MAIT cell homing in intestinal homeostasis and inflammation.Science advances · 2025Review
- Patient-derived pancreatic tumor bacteria exhibit oncogenic properties and are recognized by MAIT cells in tumor spheroids.Frontiers in immunology · 2025Article
- Mucosal associated invariant T cells: Powerhouses of the lung.Immunology letters · 2024Review
- Mucosal-associated invariant T cells modulate innate immune cells and inhibit colon cancer growth.Scandinavian journal of immunology · 2024Article
- Varicella Zoster Virus disrupts MAIT cell polyfunctional effector responses.PLoS pathogens · 2024Article
- MAIT cell activation and recruitment in inflammation and tissue damage in acute appendicitis.Science advances · 2024Article
- MAIT Cells Modulate Innate Immune Cells and Inhibit Colon Cancer Growth.bioRxiv : the preprint server for biology · 2024Article
- Insights into the tissue repair features of MAIT cells.Frontiers in immunology · 2024Review
- Tissue-resident and innate-like T cells in patients with advanced chronic liver disease.JHEP reports : innovation in hepatology · 2023Review
- The Emerging Role of MAIT Cell Responses in Viral Infections.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Classic costimulatory interactions in MAIT cell responses: from gene expression to immune regulation.Clinical and experimental immunology · 2023Article
- Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy.Cancers · 2023Review
- Glycogen-fuelled metabolism supports rapid mucosal-associated invariant T cell responses.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progress in our understanding of MR1-restricted mucosa-associated invariant T (MAIT) cells has raised interest in harnessing these cells for immunotherapy. The innate-like response characteristics, abundance in the blood, donor-unrestricted nature, and tropism for tissues make MAIT cells suitable candidates for adoptive cell transfer therapies. However, reliable methods and tools to utilize MAIT cells in such approaches are lacking. Here, we established methodology for efficient expansion of human MAIT cells in culture with high purity and yield, while preserving their functional response toward their natural ligand and increasing their cytotoxic potential. The cultured MAIT cells retained their effector memory characteristics without signs of terminal differentiation and expressed a more diverse set of chemokine receptors, potentially widening their already broad tissue tropism. To investigate the potential of MAIT cells in a context outside their main role in controlling bacterial infection, we engineered cultured MAIT cells with a new TCR specificity to mediate effective antiviral HLA class I-restricted effector function. In summary, we developed robust and effective methodology for the expansion of human MAIT cells with enhanced cytolytic capacity and for their engineering with a new specificity. These findings form a basis for the development of MAIT cells as a platform for adoptive immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.